STREAM
Strategies towards Excellence in Immuno-Oncology

MEDICAL UNIVERSITY OF WARSAW

INTERNATIONAL IMMUNO-ONCOLOGY SUMMER SCHOOL

AGENDA

MONDAY 27.06.2016
8.45 – 9.00 INTRODUCTION (presentation of STREAM project)
Short (15-minute presentations+5-minute discussions) of young scientists (PhD students, post-docs) selected on the basis of application:
9.00-9.20 Speaker TBA 1 **9.20-9.40 Speaker TBA 2** **9.40-10.00 Speaker TBA 3** **10.00-10.20 Speaker TBA 4** **10.20 – 10.40 Speaker TBA 5** **10.40-11.00 Speaker TBA 6**
11.00-11.20 COFFEE BREAK
11.20 – 11.40 Speaker TBA 7 **11.40-12.00 Speaker TBA 8** **12.00-12.20 Speaker TBA 9** **12.20 – 12.40 Speaker TBA 10** **12.40 – 13.00 Speaker TBA 11**
13.00 – 13.40 LUNCH
13.40 – 14.00 Speaker TBA 12 **14.00- 14.20 Speaker TBA 13** **14.20- 14.40 Speaker TBA 14** **14.40 – 15.00 Speaker TBA 15** **15.00- 15.20 Speaker TBA 16** **15.20- 15.40 Speaker TBA 17**
15.40-16.00 COFFEE BREAK
16.00 – 16.20 Speaker TBA 18 **16.20 – 16.40 Speaker TBA 19** **16.40- 17.00 Speaker TBA 20**

STREAM
Strategies towards Excellence in Immuno-Oncology

MEDICAL UNIVERSITY OF WARSAW

TUESDAY 28.06.2016

1	10.00-10.45
Andreas Hadjinicolaou, MD, PhD	
University of Oxford, UK	
Presentation: ''**ARGINASE 2 - a potential cancer immunomodulatory agent in AML''**	

Dr Andreas Hadjinicolaou holds BA and MA degrees in Immunology and Molecular Biology from the University of Cambridge where he also trained in Clinical Medicine (MD). He has been a research scholar at Stanford University and University of Cambridge where his research focused on autoimmune disease. He has completed an academic foundation NHS program in London as a medical doctor doing research work in cancer immunology. He is currently a Wellcome Trust Clinical Research Fellow undertaking a DPhil at the MRC Human Immunology Unit, University of Oxford with Professor Vincenzo Cerundolo, investigating the role of the tumour microenvironment in cancer immune evasion.

2	10.45-11.30
Karl-Johan Malmberg MD, PhD	
Oslo University Hospital, Norway	
Presentation: ”Harnessing Adaptive NK Cells in Cancer Immunotherapy”	

Karl-Johan Malmberg is a Hematologist and a Professor of Immunology at the University of Oslo, Norway and a Visiting Professor at the Karolinska Institute, Stockholm, Sweden. The long-term goal of the Malmberg laboratory is to advance our fundamental understanding of NK cell development and function, and use this progress to design new immunotherapeutic approaches and clinical trials for patients with cancer.

3	11.30 – 12.15
Yupo Ma, MD, PhD	
Stony Brook University, New York, USA	
Presentation: "CAR T/NK cell strategy for the treatment of relapse/refractory T cell malignancies"	

Dr. Ma is a physician-scientist, Professor, board-certified in both Pathology and Hematopathology, and expert in the field of leukemia and lymphoma. He earned his Medical Degree from Jinan University (P.R. China), College of Medicine and a Ph.D. from the University of South Alabama College of Medicine. He completed a residency in Pathology at Brown University, a clinical fellowship in Hematopathology at M.D. Anderson Cancer Center and has conducted Post Doctoral Training in Pathology at Harvard Medical School. Dr. Ma currently serves as Professor of Pathology, Medical Director of the Flow Cytometry Laboratory and Scientific Director of Stem Cell Center at Stony Brook University. His recent studies are focused on a stem cell therapy by using adult somatic cells and turning back the development of these cells so they act like embryonic cells.

As a diagnostic expert, Dr. Ma has received numerous awards including being named one of the "Best Doctors in America" for the past four years consecutively by Best Doctors, Inc. The experts who are a part of the Best Doctors in America database provide the most advanced medical expertise and knowledge to patients with serious conditions – often saving lives in the process by finding the right diagnosis and right treatment. As a physician and scientist, Dr. Ma is dedicated to finding the cures that can make a difference in the lives of patients and their families.

4	12.15-13.00
Jakub Golab, MD, PhD	
Medical University of Warsaw, Poland	
Presentation: "Photodynamic therapy of cancer"	

Prof. Jakub Golab graduated from the Faculty of Medicine, Medical University of Warsaw in 1998. He obtained his Ph.D. in 1999 in the Institute of Biostructure Research, MUW. He had postdoctoral trainings in Harvard Institutes of Medicine (1999-2000) and University of Texas Southwestern Medical School (2003). Since 2009, Prof. Jakub Golab heads the Department of Immunology at MUW, supervising the team of young group leaders who dedicated their careers to the basic and translational research in Immuno-Oncology. Prof. Golab has also been active in

privately funded drug development initiatives. Prof. Golab's major area of expertise is tumour immunology. His research concentrates on anti-tumour therapies and strategies to improve immune response against tumour cells. His major long-term goal is the development of diagnostic and therapeutic methods customized to patients' individual needs.

13.00-14.00 LUNCH

5	**14.00-14.45**
Marcin Okroj, PhD	
Medical University of Gdansk, Poland	
Presentation: "Monitoring of systemic complement activation in mAb-based immunotherapy"	

Dr Marcin Okroj obtained his master degree at the Intercollegiate Faculty of Biotechnology UG-AMG (Gdansk, Poland) in 1999 and continued his scientific career at the same place as a PhD student until defence of doctoral thesis in 2004. Afterwards he worked as postdoctoral fellow at Pasteur Institute (Paris, France) and Lund University (Malmö, Sweden). In 2010 he obtained support from Swedish Research Council and initiated his independent line of research focused on the role of complement in tumor progression, identification of novel complement inhibitors and design of new immunological methods. Currently Dr Okrój is employed at Medical University of Gdansk (Poland) as principal investigator of two projects related to therapeutic potential of the complement system, both funded by National Science Centre (NCN). He is the member of International Complement Society, European Complement Network and research program Biomarkers in Cancer Medicine (BioCare), also the author of 30 publications and named as inventor in one patent.

6	14.45-15.30
Dimitar Efremov MD, PhD	
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy	
Presentation: "The role of the B-cell receptor pathway in chronic lymphocytic leukemia: implications for biology and treatment"	

Prof. Dimitar Efremov is Staff Scientist and Head of the Molecular Hematology Group of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy. Prof. Efremov obtained his MD degree at the Faculty of Medicine in Skopje, Republic of Macedonia, where he also completed his specialization in internal medicine and training in hematology. He obtained his PhD degree from the Faculty of Medicine, Maastricht University, Maastricht, The Netherlands and received fellowships from the Medical College of Georgia, Augusta, GA, USA. In 1994 he became Staff Scientist at the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy, where he remained until 1998. He subsequently returned to the Department of Hematology, Faculty of Medicine, Skopje, Republic of Macedonia, where he was appointed as an Associate Professor of Internal Medicine. In 2003 he moved again to Italy and established the ICGEB Molecular Hematology Group and the ICGEB Outstation in Rome, which he headed until his move to the ICGEB Headquarters in Trieste in November 2015. He was also elected Associate Professor of Molecular biology at the University of Nova Gorica in Slovenia in 2010 and received the Italian national habilitation for Associate Professor of Hematology in 2013. In 2015 he was elected external member of the Macedonian Academy of Sciences and Arts. Prof. Efremov's primary research interest is chronic lymphocytic leukemia, particularly the molecular mechanisms governing the development and progression of the disease and identification of novel targeted therapies. He has authored more than 100 articles in peer-reviewed medical journals, including *Blood*, *Journal of Clinical Investigation*, *Journal of Experimental Medicine, Leukemia and the Proceedings of the National Academy of Sciences USA*, and has received prestigious grants from various national and international organizations, including the Leukemia & Lymphoma Society and the Italian Association for Cancer Research.

7	**15.30-16.15**
Dinis Calado, PhD	
The Francis Crick Institute, London, UK	
Presentation: TBA	